Risk prediction model for mortality in microscopic polyangiitis: multicentre REVEAL cohort study.

"Declarations Ethics approval and consent to participateThis study adhered to the principles of the Declaration of Helsinki and its amendments. Approval was granted by the Ethics Committee of Osaka Medical and Pharmaceutical University and the Faculty of Medicine (Approval No. 1529), as well as by the individual participating centres, namely Kyoto University (Approval No. R1540) and Osaka Metropolitan University (Approval No. 2021-074). The Ethics Committee of Kyoto University waived the need for patient informed consent given the anonymized nature of the data. Written informed consent was obtained from patients at other participating institutes. Consent for publicationNot applicable. Competing interestsTK received payments for lectures from AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. SM received a research grant from the Japan Intractable Diseases Research Foundation and payment for lectures from AbbVie. RW received research grants from AbbVie and speaker fees from Asahi Kasei, Chugai, Eli Lilly, GSK, and Sanofi. RH received research grants from GSK and speaker fees from AbbVie, Asahi Kasei, Brystol-Meyers Squibb, Eisai, Eli Lilly, GSK, Kissei, and Pfizer. MH received research grants and speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, and Tanabe Mitsubishi. TT received research grants and/or speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol-Meyers Squibb, Chugai, Eisai, Eli Lilly, Janssen Pharma, Nihon Shinyaku, Mitsubishi Tanabe, Takeda, and Pfizer. The other authors (AO, DN, TG, AM, MS, KK, and WY) declare no conflicts of interest. Competing interests TK received payments for lectures from AbbVie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. SM received a research grant from the Japan Intractable Diseases Research Foundation and payment for lectures from AbbVie. RW received research grants from AbbVie and speaker fees from Asahi Kasei, Chugai, Eli Lilly, GSK, and Sanofi. RH received research grants from GSK and speaker fees from AbbVie, Asahi Kasei, Brystol-Meyers Squibb, Eisai, Eli Lilly, GSK, Kissei, and Pfizer. MH received research grants and speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, and Tanabe Mitsubishi. TT received research grants and/or speaker fees from AbbVie, Asahi Kasei, Astellas, Brystol-Meyers Squibb, Chugai, Eisai, Eli Lilly, Janssen Pharma, Nihon Shinyaku, Mitsubishi Tanabe, Takeda, and Pfizer. The other authors (AO, DN, TG, AM, MS, KK, and WY) declare no conflicts of interest."

"Funding None."